Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity | Zendy

Athanasios Papadas | Zendy; Garrett Arauz | Zendy; Alexander Cicala | Zendy; Joshua Wiesner | Zendy; Fotis Asimakopoulos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity

Author(s) -

Athanasios Papadas,

Garrett Arauz,

Alexander Cicala,

Joshua Wiesner,

Fotis Asimakopoulos

Publication year - 2020

Publication title -

journal of histochemistry and cytochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.971

H-Index - 124

eISSN - 1551-5044

pISSN - 0022-1554

DOI - 10.1369/0022155420937098

Subject(s) - versican , immune system , extracellular matrix , inflammation , cancer research , tumor progression , tumor microenvironment , biology , immunology , cancer , microbiology and biotechnology , proteoglycan , genetics

Versican is an extracellular matrix proteoglycan with key roles in multiple facets of cancer development, ranging from proliferative signaling, evasion of growth-suppressor pathways, regulation of cell death, promotion of neoangiogenesis, and tissue invasion and metastasis. Multiple lines of evidence implicate versican and its bioactive proteolytic fragments (matrikines) in the regulation of cancer inflammation and antitumor immune responses. The understanding of the dynamics of versican deposition/accumulation and its proteolytic turnover holds potential for the development of novel immune biomarkers as well as approaches to reset the immune thermostat of tumors, thus promoting efficacy of modern immunotherapies. This article summarizes work from several laboratories, including ours, on the role of this central matrix proteoglycan in tumor progression as well as tumor-immune cell cross-talk:

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research